Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3015% below fair value
$26.63−0.88 (-3.20%)
Close on Nov 19, 2026Market cap $1.37BP/E –Yield 0.00%
Immunocore net income
Net income is the profit left for shareholders after every expense, interest and tax.
Immunocore's net income for the twelve months ending Jun 30, 2026 was -$18.07M. For fiscal 2025 it was -$35.51M. The highest annual figure on record is -$35.51M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$35.51M | – |
| FY2024 | Dec 31, 2024 | -$51.09M | – |
| FY2023 | Dec 31, 2023 | -$55.29M | – |
| FY2022 | Dec 31, 2022 | -$52.54M | – |
| FY2021 | Dec 31, 2021 | -$180.03M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$808.00K | – |
| Q1 FY2026 | Mar 31, 2026 | $12.97M | +158.2% |
| Q4 FY2025 | Dec 31, 2025 | -$30.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$177.00K | -102.0% |
| Q2 FY2025 | Jun 30, 2025 | -$10.30M | – |
| Q1 FY2025 | Mar 31, 2025 | $5.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.77M | – |
| Q3 FY2024 | Sep 30, 2024 | $8.74M | +864.2% |
| Q2 FY2024 | Jun 30, 2024 | -$11.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.44M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.73M | – |
| Q3 FY2023 | Sep 30, 2023 | $906.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.45M | – |
See a number that looks wrong?